Biotechnology

The advisory giant's acquisition of a Boston-based specialist signals a strategic push into the high-stakes, high-growth world of life sciences and biotech.

Israeli startup Protai is set to reveal promising preclinical data for its cancer drug, PRT-001, powered by its unique proteomics-aware AI platform.

A new partnership between South Korea's GCCL and Europe's Medicover MICS promises to streamline drug development by creating a seamless East-West axis.

Swiss pharma Santhera appoints Stifel as advisor, a strategic move to fuel the global rollout of its DMD drug AGAMREE amid a complex biotech funding market.

Belgian biotech Agomab Therapeutics secures $200 million in its Nasdaq debut, fueling its mission to develop therapies for debilitating fibrotic conditions.

A national report card gives the U.S. a 'B' on rare disease policy, but stark state-by-state disparities leave millions vulnerable to financial ruin.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

A new 'zero-disruption' plate from TheWell Bioscience aims to solve key challenges in organoid research, promising more reliable data for drug discovery.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

A new initiative backed by the Japanese government aims to transform the nation's world-class scientific research into globally competitive biotech companies.

A Chinese biotech's novel nasal spray flu vaccine enters trials. Its unique design could finally make it safe for the elderly and expand global access.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

From its unique seat at the World Government Summit, CanSinoBIO unveils its next-gen vaccine pipeline and global strategy to fight humanity's oldest diseases.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

With five conferences in its sights, Voyager Therapeutics is making a major push to win over investors ahead of a pivotal year for its neurological pipeline.

A £500,000 philanthropic investment fuels five pioneering research projects at Oxford, aiming to unlock new treatments for a devastating rare disease.

With a new flexible, founder-first model, Activation Capital's Frontier BioHealth program aims to bridge the commercialization gap for life sciences startups.

A groundbreaking dual-payload ADC from Kanghong Pharmaceutical has entered clinical trials, a major milestone in oncology accelerated by partner BioDlink.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.